Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Author's Avatar
Feb 22, 2023

- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -